Crossmark

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis

Crossref DOI link: https://doi.org/10.1038/s41408-022-00770-x

Published Online: 2022-12-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kwag, Daehun https://orcid.org/0000-0003-3353-882X
Cho, Byung-Sik https://orcid.org/0000-0002-4524-6616
Bang, Su-Yeon

Lee, Jong Hyuk https://orcid.org/0000-0001-8465-2791
Min, Gi-June

Park, Sung-Soo https://orcid.org/0000-0002-8826-4136
Park, Silvia

Yoon, Jae-Ho https://orcid.org/0000-0002-2145-9131
Lee, Sung-Eun

Eom, Ki-Seong

Kim, Yoo-Jin

Lee, Seok https://orcid.org/0000-0002-9442-9814
Min, Chang-Ki

Cho, Seok-Goo https://orcid.org/0000-0002-5429-4839
Lee, Jong Wook https://orcid.org/0000-0003-2949-4166
Kim, Hee-Je https://orcid.org/0000-0003-4098-3366
License Information

Text and Data Mining valid from 2022-12-19

Version of Record valid from 2022-12-19
More Information

Article History

Received: 16 September 2022

Revised: 7 December 2022

Accepted: 7 December 2022

First Online: 19 December 2022

Competing interests

: The authors declare no competing interests.